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III- ABSTRACT  
Background  
The burden of dyslipidaemia in Africa remains inadequately characterised. We aimed to estimate 
the prevalence of dyslipidaemia in African adults from hospital-based and community-based 
studies.  
Methods  
In this systematic review and meta-analysis, we searched MEDLINE via PubMed, EMBASE, 
African Journals Online, and African Index Medicus for studies published between Jan 1, 1980, 
and July 31, 2017, without language restriction. We assessed methodological quality of all 
crosssectional studies reporting on the prevalence of elevated concentrations of total cholesterol, 
LDL cholesterol, or triglycerides, or low concentrations of HDL cholesterol in adults residing in 
African countries. We excluded reports on Africans living outside Africa, studies of individuals 
selected on the basis of existing dyslipidaemia or those including children and adolescents, and 
case series with a small sample size. The most frequently used cutoffs in the included studies were 
chosen for the subgroup analysis. We used random-effect model meta-analysis to derive the pooled 
prevalence of elevated total cholesterol, low HDL cholesterol, elevated LDL cholesterol, and 
elevated triglyceride concentrations. This study is registered with PROSPERO, number 
CRD42014015376. Findings  
177 studies (294063 participants) were included in the meta-analysis. The pooled prevalence of 
dyslipidaemia in the general population from population-based studies was 25·5% (95% CI 20·0– 
31·4) for elevated concentrations of total cholesterol with a cutoff of at least 5·2 mmol/L, 37·4%  
(29·4–45·7) for low concentrations of HDL cholesterol with a cutoff of less than 1·0 mmol/L,  
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28·6% (15·8–43·5) for elevated concentrations of LDL cholesterol with a cutoff of at least 3·3 
mmol/L, and 17·0% (11·9–22·7) for elevated concentrations of triglycerides with a cutoff of at 
least 1·7 mmol/L.  
Interpretation  
The prevalence of dyslipidaemia is high in the general adult population in Africa. Ongoing efforts 
to reduce cardiovascular diseases in Africa should integrate effective detection and treatment of 
dyslipidaemia.  
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VII- APPENDIX  
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modified for the purpose of this dissertation: the table of contents has been removed and the numbering 
is linked to the whole document.  
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Supplementary Table 1. Summary and comparison statistics for dyslipidaemia based on total cholesterol  
Groups  Subgroups  Cut-off, 
mmol/L  
N  
studies  
N 
participants  
% (95% CI)  I2 (95% CI)  H (95% CI)  P  
heterogeneity  
P Egger  
test  
P-diff 
criteria  
P-diff 
subgroups  
COMMUNITY-BASED  
NON-DISEASE 
SPECIFIC  
                      
All   
  Imprecise  1  452  25.2 (21.3-29.3)  NA  NA  NA  NA  < 0.0001  NA  
    5.2  41  85440  23.6 (18.4-29.2)  99.7 (99.7-99.7)  18.5 (17.4-19.2)  <0.0001  0.019      
    6.5  20  34054  11.0 (7.1-15.5)  99.3 (99.2-99.4)  12.4 (11.5-13.3)  <0.0001  0.943      
                        
By Sex  Males  5.2  21  22184  25.2 (17.3-34.1)  99.5 (99.4-99.6)  14.1 (13.2-15.0)  <0.0001  0.011  0.003  0.370  
  Females  5.2  24  31053  30.5 (23.1-38.6)  99. 5 (99.5-99.6)  14.6 (13.8-15.5)  <0.0001  0.006  0.0003    
  Males  6.5  16  14004  10.9 (6.3-16.5)  98.9 (98.7-99.1)  9.6 (8.7-10.5)  <0.0001  0.951    0.492  
  Females  6.5  16  16584  13.5 (8.7-19.0)  98.9 (98.7-99.)  9.7 (8.8-0.6)  <0.0001  0.403      
                        
By Region  Central  5.2  1  1573  1.7 (1.1-2.4)  NA  NA  NA  NA  <0.0001  <0.0001  
  Eastern  5.2  9  40711  19.3 (11.6-28.5)  99.8 (99.8-99.8)  21.6 (20.1-23.2)  <0.0001  0.007  0.510    
  Northern  5.2  9  21381  31.9 (25.4-38.8)  99.1 (98.8-99.3)  10.3 (9.1-11.7)  <0.0001  0.516  <0.0001    
  Southern  5.2  6  6746  32.6 (15.2-52.9)  99.7 (99.6-99.7)  17.2 (15.4-19.1)  <0.0001  0.695  0.424    
  Western  5.2  16  15029  20.3 (12.2-29.8)  99.4 (99.3-99.5)  13.1 (12.1-14.1)  <0.0001  0.652  <0.0001    
  Central  6.5  1  1871  7.1 (6.0-8.3)  NA  NA  NA  NA    <0.0001  
  Eastern  6.5  9  21293  15.6 (9.2-23.4)  99.5 (99.4-99.6)  14.1 (12.8-15.6)  <0.0001  0.653      
  Northern  6.5  6  4868  9.5 (7.2-12.1)  87.5 (75.1-93.7)  2.8 (2.0-4.0)  <0.0001  0.917      
  Southern  6.5  1  976  24.9 (22.2-27.7)  NA  NA  NA  NA      
  Western  6.5  3  5046  1.9 (0.7-3.5)  88.1 (66.7-95.7)  2.9 (1.7-4.8)  0.0002  0.853      
                        
By Setting  Urban  5.2  21  26724  28.7 (21.2-36.7)  99.5 (99.4-99.5)  13.8 (12.9-14.7)  <0.0001  0.707  0.0003  <0.0001  
  Rural  5.2  15  33654  9.7 (5.7-14.6)  99.4 (99.3-99.5)  13.1 (12.1-14.4)  <0.0001  0.588  0.003    
  Urban  6.5  8  5124  9.9 (4.8-16.7)  98.0 (97.3-98.6)  7.2 (6.1-8.5)  <0.0001  0.544    0.012  
  Rural  6.5  5  4523  3.0 (1.5-5.1)  90.3 (80.3-95.2)  3.2 (2.3-4.6)  <0.0001  0.242      
                        
By Representativeness  National  5.2  8  18845  35.9 (27.2-45.1)  99.4 (99.2-99.5)  12.9 (11.5-14.4)  <0.0001  0.006  0.002  0.005  
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  Subnational   5.2  33  66595  20.8 (15.4-26.8)  99.7 (99.7-99.7)  18.0 (17.3-18.8)  <0.0001  0.051  0.005    
  National  6.5  7  18567  13.8 (6.1-24.2)  99.7 (99.6-99.7)  17.7 (16.1-19.5)  <0.0001  0.465    0.428  
  Subnational   6.5  12  13616  9.8 (5.4-15.2)  98.9 (98.6-99.1)  9.4 (8.6-10.6)  <0.0001  0.300      
                        
By Publication date  Published <2010  5.2  16  31416  25.4 (17.2-34.7)  99.7 (99.6-99.7)  17.4 (16.4-18.5)  <0.0001  0.488  0.022  0.588  
  Published >2010  5.2  25  54024  22.4 (16.0-29.0)  99.7 (99.7-99.7)  18.7 (17.9-19.6)  <0.0001  0.021  0.001    
  Published <2010  6.5  12  23676  13.6 (8.5-19.6)  99.3 (99.2-99.5)  12.3 (11.2-13.5)  <0.0001  0.954    0.129  
  Published >2010  6.5  8  10378  7.5 (3.0-13.7)  99.0 (98.7-99.2)  10.1 (8.8-11.5)  <0.0001  0.314      
                        
By Median sample size  Lower (<1263)  5.2  20  11814  26.2 (16.9-36.7)  99.3 (99.2-99.4)  12.3 (11.4-13.2)  <0.0001  0.355  0.003  0.400  
  Higher (>1263)  5.2  21  73626  21.2 (15.1-28.1)  99.8 (99.8-99.8)  22.0 (21.0-23.0)  <0.0001  0.003  0.056    
  Lower (<1074)  6.5  10  7026  9.9 (5.1-159)  98.3 (97.8-98.7)  7.7 (6.7-8.8)  <0.0001  0.309    0.612  
  Higher (>1074)  6.5  10  27028  12.1 (6.4-19.2)  99.6 (99.5-99.7)  16.2 (14.9-17.7)  <0.0001  0.648      
                        
Groups  Subgroups  Cut-off, 
mmol/L  
N  
studies  
N 
participants  
% (95% CI)  I2 (95% CI)  H (95% CI)  P  
heterogeneity  
P Egger  
test  
P-diff 
criteria  
P-diff 
subgroups  
HOSPITAL-BASED  
NON-DISEASE 
SPECIFIC  
                      
All   
  4.5  4  2185  55.4 (39.4-70.8)  95.5 (91.4-97.7)  4.7 (3.4-6.5)  <0.0001  0.071  <0.0001    
    5.2  12  5967  29.7 (12.7-50.1)  99.3 (99.1-99.4)  11.6 (10.6-12.8)  <0.0001  0.003      
    6.5  8  2663  10.6 (7.1-14.7)  88.7 (80.1-93.6)  3.0 (2.2-4.0)  <0.0001  0.932      
    7.0  1  172  2.3 (0.5-5.2)  NA  NA  NA  NA      
                        
                        
HOSPITAL-BASED 
DISEASE SPECIFIC  
                      
Diabetes mellitus    5.2  9  2100  34.4 (23.3-46.4)  96.8 (95.4-97.8)  5.6 (4.7-6.7)  <0.0001  0.694  0.746    
Diabetes mellitus    6.5  2  470  37.8 (22.3-54.7)  92.9 (76.2-97.9)  3.8  0.0002  NA      
                        
Diabetic nephropathy    5.2  1  72  62.5 (51.0-73.4)  NA  NA  NA  NA      
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HIV    5.2  29  29372  24.2 (19.7-28.9)  98.5 (98.3-98.7)  8.2 (7.6-8.8)  <0.0001  0.012  0.007    
HIV    6.5  2  6785  7.7 (1.6-17.8)  97.3 (93.1-98.9)  6.1  <0.0001  NA      
                        
Hypertension    5.2  7  2136  38.0 (23.8-53.4  97.9 (96.9-98.5)  6.9 (5.7-8.3)  <0.0001  0.946  0.032    
Hypertension    6.5  2  283  15.8 (3.4-34.8)  92.8 (76.0-97.9)  3.7  0.0002  NA      
                        
MI/CHD/HF    5.2  2  6992  37.7 (0.2-90.8)  99.3 (98.6-99.6)  11.6  <0.0001  NA  0.568    
MI/CHD/HF    6.5  1  102  21.6 (14.1-30.1)  NA  NA  NA  NA      
                        
Obesity    5.2  3  219  25.4 (1.0-64.7)  96.8 (93.4-98.4)  5.6 (3.9-8.0)  <0.0001  0.461      
                        
Stroke    6.5  2  382  8.1 (5.5-11.1)  0.0  1.0  0.976  NA      
                        
Systemic lupus 
erythematous  
  5.2  1  221  51.1 (44.5-57.7)  NA  NA  NA  NA      
                        
POPULATION-BASED 
DISEASE SPECIFIC  
                      
Diabetes mellitus    5.2  3  2352  34.3 (24.8-44.4)  95.6 (90.4-98.0)  4.8 (3.2-7.1)  <0.0001  0.341      
                        
Hypertension    5.2  1  1376  11.6 (10.0-13.4)  NA  NA  NA  NA  0.034    
    6.5  1  710  14.9 (12.4-17.6)  NA  NA  NA  NA      
                        
Obesity    5.2  1  154  40.3 (32.6-48.1)  NA  NA  NA  NA      
HIV: human immunodeficiency syndrome; MI: myocardial infarction; CHD: coronary heart disease; HF: heart failure  
    
Supplementary Table 2. Summary and comparison statistics for dyslipidaemia based on high-density lipoprotein cholesterol  
Groups  Subgroups  Cut-off, 
mmol/L  
N  
studies  
N 
participants  
% (95% CI)  I2 (95% CI)  H (95% CI)  P  
heterogeneity  
P Egger  
test  
P-diff 
criteria  
P-diff 
subgroups  
COMMUNITY-BASED  
NON-DISEASE 
SPECIFIC  
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All   
  0.9  6  5771  19.5 (10.5-30.4)  98.9 (98.5-99.2)  9.6 (8.2-11.3)  <0.0001  0.801  0.002    
    1.0  30  49857  41.1 (33.0-49.4)  99.7 (99.7-99.7)  18.5 (17.8-19.4)  <0.0001  0.002      
                        
                        
By Sex  Males  1.0  15  12704  33.9 (22.3-46.7)  99.5 (99.4-99.6)  14.0 (13.0-15.1)  <0.0001  0.040    0.127  
  Females  1.0  17  17781  48.0 (35.2-60.8)  99.6 (99.6-99.7)  16.8 (15.8-17.9)  <0.0001  0.008      
                        
By Region  Central  1.0  1  452  10.0 (7.4-12.9)  NA  NA  NA  NA    <0.0001  
  Eastern  1.0  5  25213  53.8 (37.7-69.5)  99.8 (99.8-99.9)  25.2 (230-27.6)  <0.0001  0.0007      
  Northern  1.0  6  6948  34.2 (20.7-49.2)  99.3 (99.1-99.5)  12.3 (10.8-14.2)  <0.0001  0.392      
  Southern  1.0  6  7295  48.6 (33.8-63.5)  99.4 (99.2-99.5)  12.9 (11.3-14.8)  <0.0001  0.619      
  Western  1.0  12  9949  38.7 (28.4-49.5)  99.1 (98.9-99.3)  10.5 (9.5-11.6)  <0.0001  0.693      
                        
By Setting  Urban  1.0  18  12762  31.9 (24.0-40.5)  99.0 (98.8-99.2)  10.0 (9.2-10.9)  <0.0001  0.370    0.0097  
  Rural  1.0  12  23982  49.7 (39.3-60.1)  99.6 (99.5-99.6)  15.1 (13.9-16.4)  <0.0001  0.056      
                        
By Representativeness  National  1.0  3  6074  27.6 (15.0-42.3)  99.3 (98.9-99.6)  12.0 (9.7-15.0)  <0.0001  0.965    0.077  
  Subnational   1.0  27  43783  42.7 (34.5-51.0)  99.7 (99.6-99.7)  17.2 (16.4-18.1)  <0.0001  0.0008      
                        
By Publication date  Published <2010  1.0  4  3246  18.4 (14.8-22.3)  85.9 (65.4-94.2)  2.7 (1.7-4.2)  <0.0001  0.528    <0.0001  
  Published >2010  1.0  26  46661  45.0 (36.7-53.4)  99.7 (99.7-99.7)  18.0 (17.1-18.8)  <0.0001  0.010      
                        
By Median sample size  Lower (<999)  1.0  15  7483  34.5 (20.7-49.8)  99.4 (99.4-99.5)  13.5 (12.5-14.6)  <0.0001  0.945    0.159  
  Higher (>999)  1.0  15  42374  47.7 (37.5-58.0)  99.8 (99.7-99.8)  21.1 (20.0-22.3)  <0.0001  0.003      
                        
HOSPITAL-BASED  
NON-DISEASE 
SPECIFIC  
                      
All   
  0.9  4  534  37.7 (0.3-90.0)  99.4 (99.2-99.6)  13.2 (11.1-15.6)  <0.0001  0.633  0.976    
    1.0  22  6911  38.6 (29.8-47.8)  98.2 (97.9-98.5)  7.5 (6.8-8.2)  <0.0001  0.071      
 28  
  
                        
HOSPITAL-BASED 
DISEASE SPECIFIC  
                      
Bipolar mood disorders    0.9  1  130  59.2 (50.6-67.6)  NA  NA  NA  NA      
                        
Diabetes mellitus    0.8  1  218  15.6 (11.1-20.7)  NA  NA  NA  NA  <0.0001    
Diabetes mellitus    0.9  2  448  58.3 (53.6-62.8)  0.0  1.0  0.825  NA      
Diabetes mellitus    1.0  14  3159  42.1 (32.3-52.2)  96.8 (95.8-97.6)  5.6 (4.9-6.5)  <0.0001  0.148      
Diabetes mellitus    1.6  1  401  11.5 (8.5-14.8)  NA  NA  NA  NA      
                        
Groups  Subgroups  Cut-off, 
mmol/L  
N  
studies  
N 
participants  
% (95% CI)  I2 (95% CI)  H (95% CI)  P  
heterogeneity  
P Egger  
test  
P-diff 
criteria  
P-diff 
subgroups  
Diabetic nephropathy    1.0  1  72  58.3 (46.7-69.5)  NA  NA  NA  NA      
                        
HIV    0.9  1  327  32.4 (27.4-37.6)  NA  NA  NA  NA  <0.0001    
HIV    1.0  30  70348  53.7 (48.6-58.8)  99.1 (99.0-99.2)  10.6 (10.0-11.33)  <0.0001  0.013      
HIV    1.2  1  304  45.7 (40.1-51.3)  NA  NA  NA  NA      
HIV    1.3  1  159  56.6 (48.8-64.2)  NA  NA  NA  NA      
                        
Hypertension    0.9  1  100  3.0 (0.4-7.5)  NA  NA  NA  NA  <0.0001    
Hypertension    1.0  9  3978  39.4 (29.4-9.9)  97.4 (96.3-98.1)  6.2 (5.2-7.3)  0.685        
Hypertension    1.2  1  403  30.0 (25.6-34.6)  NA  NA  NA  NA      
                        
Mental illness    1.0  1  276  52.5 (46.6-58.4)  NA  NA  NA  NA      
                        
Obesity    1.0  1  129  21.7 (15.0-29.3)  NA  NA  NA  NA      
                        
Post-menopause    1.0  1  183  66.1 (59.1-72.8)  NA  NA  NA  NA      
                        
Pregnancy    1.0  2  725  7.7 (5.8-9.8)  0.0  1.0  0.501  NA      
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Psoriasis    1.0  1  150  56.7 (48.6-64.5)  NA  NA  NA  NA      
                        
Rheumatoid arthritis    1.0  1  92  95.7 (90.3-99.1)  NA  NA  NA  NA      
                        
Skin disease    1.0  1  300  13.3 (9.7-17.4)  NA  NA  NA  NA      
                        
Systemic lupus 
erythematosus  
  1.0  1  221  44.8 (38.3-51.4)  NA  NA  NA  NA      
                        
POPULATION-BASED 
DISEASE SPECIFIC  
                      
Diabetes mellitus    1.0  5  2526  39.5 (26.7-53.0)  97.3 (95.6-98.3)  6.1 (4.8-7.8)  <0.0001  0.952      
Hypertension    0.9  1  710  25.1 (21.9-28.3)  NA  NA  NA  NA      
Obesity    1.0  1  154  27.9 (21.1-35.3)  NA  NA  NA  NA      
HIV: human immunodeficiency syndrome; MI: myocardial infarction; CHD: coronary heart disease; HF: heart failure  
    
Supplementary Table 3. Summary and comparison statistics for dyslipidaemia based on low-density lipoprotein cholesterol  
Groups  Subgroups  Cut-off, 
mmol/L  
N  
studies  
N 
participants  
% (95% CI)  I2 (95% CI)  H (95% CI)  P  
heterogeneity  
P Egger  
test  
P-diff 
criteria  
P-diff 
subgroups  
COMMUNITY-BASED  
NON-DISEASE 
SPECIFIC  
                      
All   
  2.6  2  1830  21.3 (16.6-26.5)  81.2 (19.9-95.6)  2.3  0.021  NA  0.226    
    3.3  14  23844  25.7 (16.2-36.6)  99.6 (99.6-99.7)  16.9 (15.8-18.1)  <0.0001  0.002      
    4.0  5  5921  13.5 (5.7-24.0)  99.1 (98.7-99.4)  10.6 (8.9-12.5)  <0.0001  0.484      
                        
By Sex  Males  3.3  7  8041  21.6 (10.5-35.2)  99.3 (99.1-99.5)  11.9 (10.4-13.5)  <0.0001  0.004    0.230  
  Females  3.3  7  10852  34.1 (19.2-50.7)  99.6 (99.5-99.7)  16.0 (14.4-17.7)  <0.0001  0.001      
                        
By Region  Central  3.3  0  NA  NA  NA  NA  NA  NA    0.305  
  Eastern  3.3  3  15689  14.6 (6.6-25.0)  99.5 (99.3-99.7)  14.9 (12.3-17.9)  <0.0001  0.029      
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  Northern  3.3  0  NA  NA  NA  NA  NA  NA      
  Southern  3.3  3  2824  25.1 (3.5-57.7)  99.7 (99.6-99.8)  18.0 (15.2-21.2)  <0.0001  0.809      
  Western  3.3  8  5331  30.7 (12.4-52.8)  99.6 (99.5-99.7)  15.6 (14.2-17.2)  <0.0001  0.055      
                        
By Setting  Urban  3.3  6  3822  35.0 (24.8-46.0)  97.6 (96.4-98.4)  6.5 (5.3-8.0)  <0.0001  0.612    <0.0001  
  Rural  3.3  7  19337  9.4 (5.2-14.6)  98.9 (98.6-99.2)  9.7 (8.4-11.3)  <0.0001  0.329      
                        
By Representativeness  National  3.3  0  NA  NA  NA  NA  NA  NA    NA  
  Subnational   3.3  14  23844  25.7 (16.2-36.6)  99.6 (99.6-99.7)  16.9 (15.8-18.1)  <0.0001  0.002      
                        
By Publication date  Published <2010  3.3  1  441  44.9 (40.3-49.7)  NA  NA  NA  NA    0.0008  
  Published >2010  3.3  13  24403  24.4 (15.0-35.2)  99.6 (99.6-99.7)  16.8 (15.7-18.1)  <0.0001  0.005      
                        
By Median sample size  Lower (< 671)  3.3  7  2291  44.2 (33.6-55.0)  96.2 (94.1-97.6)  5.1 (4.1-6.4)  <0.0001  0.709    0.003  
  Higher (> 671)  3.3  7  21553  11.3 (4.9-19.8)  99.6 (99.5-99.7)  16.3 (14.7-18.1)  <0.0001  0.204      
                        
HOSPITAL-BASED  
NON-DISEASE 
SPECIFIC  
                      
All  
  2.6  6  2532  48.9 (34.7-63.1)  96.6 (94.6-97.9)  5.5 (4.3-6.9)  <0.0001  0.432  <0.0001    
    3.3  7  881  18.5 (6.7-34.2)  96.4 (94.5-97.7)  5.3 (4.3-6.6)  <0.0001  0.958      
    4.0  4  1094  10.3 (2.2-23.0)  96.2 (92.9-98.0)  5.1 (3.8-7.0)  <0.0001  0.196      
                        
                        
HOSPITAL-BASED 
DISEASE SPECIFIC  
                      
Chronic kidney disease    3.3  1  217  41.0 (34.5-47.6)  NA  NA  NA  NA      
                        
Diabetes mellitus    2.6  5  564  40.4 (25.9-55.8)  92.0 (84.2-95.9)  3.5 (2.5-4.9)  <0.0001  0.697  <0.0001    
Diabetes mellitus    3.3  8  2067  50.1 (37.6-62.3)  96.9 (95.5-97.9)  5.7 (4.7-9.6)  <0.0001  0.933      
Diabetes mellitus    4.0  2  520  4.2 (0.0-15.8)  95.3 (86.2-98.4)  4.6  <0.0001  NA      
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Groups  Subgroups  Cut-off, 
mmol/L  
N  
studies  
N 
participants  
% (95% CI)  I2 (95% CI)  H (95% CI)  P  
heterogeneity  
P Egger  
test  
P-diff 
criteria  
P-diff 
subgroups  
                        
Diabetic nephropathy    3.3  1  72  45.8 (34.4-57.5)  NA  NA  NA  NA      
                        
HIV    2.6  1  406  44.1 (39.3-48.9)  NA  NA  NA  NA  <0.0001    
HIV    3.3  14  64453  20.8 (16.8-25.1)  98.9 (98.7-99.1)  9.6 (8.6-10.6)  <0.0001  0.129      
HIV    4.0  2  7701  2.5 (2.2-2.9)  0.0  1.0  0.706  NA      
                        
Hypertension    2.6  3  1262  34.6 (9.5-65.5)  98.9 (98.3-99.4)  9.7 (7.6-12.5)  <0.0001  0.355  0.917    
Hypertension    3.3  3  618  32.7 (17.5-50.0)  93.4 (84.1-97.3)  3.9 (2.5-6.1)  <0.0001  0.479      
                        
Obesity    2.6  1  129  9.3 (4.8-15.0)  NA  NA  NA  NA      
                        
Rheumatoid arthritis    4.0  1  92  48.9 (38.7-59.2)  NA  NA  NA  NA      
                        
Systemic lupus 
erythematosus  
  3.3  1    30.3 (24.4-36.6)  NA  NA  NA  NA      
                        
POPULATION-BASED 
DISEASE SPECIFIC  
                      
Diabetes mellitus    2.6  1  74  44.6 (33.4-56.1)  NA  NA  NA  NA      
Hypertension    4.0  1  710  16.5 (13.8-19.3)  NA  NA  NA  NA      
Obesity    3.3  1  154  48.7 (40.8-56.6)  NA  NA  NA  NA      
HIV: human immunodeficiency syndrome; MI: myocardial infarction; CHD: coronary heart disease; HF: heart failure  
    
Supplementary Table 4.  Summary and comparison statistics for dyslipidaemia based on low-density lipoprotein cholesterol  
Groups  Subgroups  Cut-off, 
mmol/L  
N  
studies  
N 
participants  
% (95% CI)  I2 (95% CI)  H (95% CI)  P  
heterogeneity  
P Egger  
test  
P-diff 
criteria  
P-diff 
subgroups  
COMMUNITY-BASED  
NON-DISEASE 
SPECIFIC  
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All   
  1.7  39  65267  16.4 (11.8-21.6)  99.6 (99.6-99.7)  16.8 (16.2-17.5)  <0.0001  0.755  <0.0001    
    2.2  14  35833  10.0 (6.8-13.7)  99.1 (98.9-99.3)  10.7 (9.7-11.7)  <0.0001  0.475      
    5.2  1  441  5.0 (3.1-7.2)  NA  NA  NA  NA      
                        
By Sex  Males  1.7  16  13194  16.4 (10.5-23.3)  98.9 (98.6-99.1)  9.4 (8.5-10.3)  <0.0001  0.102    0.986  
  Females  1.7  19  21730  16.4 (9.8-24.3)  99.5 (99.4-99.6)  14.1 (13.2-15.1)  <0.0001  0.602      
                        
By Region  Central  1.7  2  2025  3.3 (0.0-14.5)  98.4 (96.4-99.3)  7.9  <0.0001  NA    0.0005  
  Eastern  1.7  7  27643  18.7 (11.9-26.5)  99.5 (99.4-99.6)  14.9 (13.3-16.6)  <0.0001  0.099      
  Northern  1.7  10  17563  29.3 (20.0-39.5)  99.5 (99.4-99.6)  14.0 (12.7-15.3)  <0.0001  0.180      
  Southern  1.7  5  6309  21.5 (12.5-32.2)  98.9 (98.4-99.2)  9.6 (8.0-11.5)  <0.0001  0.885      
  Western  1.7  15  11727  9.1 (4.6-14.9)  98.9 (98.6-99.1)  9.4 (8.6-10.4)  <0.0001  0.830      
                        
By Area  Urban  1.7  20  12784  18.8 (12.2-26.4)  99.0 (98.9-99.2)  10.2 (9.4-11.1)  <0.0001  0.826    0.007  
  Rural  1.7  15  20739  8.3 (4.9-12.5)  98.8 (98.5-99.0)  9.2 (8.3-10.1)  <0.0001  0.923      
                        
By Representativeness  National  1.7  5  15588  34.0 (19.4-50.3)  99.8 (99.7-99.8)  21.0 (18.9-23.3)  <0.0001  0.313    0.009  
  Subnational   1.7  34  49679  14.2 (10.7-18.1)  99.3 (99.2-99.3)  11.6 (11.0-12.3)  <0.0001  0.109      
                        
By Publication date  Published <2010  1.7  8  16486  17.2 (8.8-27.7)  99.5 (99.4-99.6)  14.4 (13.0-16.0)  <0.0001  0.380    0.870  
  Published >2010  1.7  31  48781  16.2 (10.9-22.4)  99.7 (99.6-99.7)  17.1 (16.3-17.9)  <0.0001  0.768      
                        
By Median sample size  Lower (≤ 1012)  1.7  20  9342  15.7 (10.1-22.3)  98.5 (98.2-98.7)  8.1 (7.4-8.9)  <0.0001  0.345    0.781  
  Higher (> 1012)  1.7  19  55925  17.2 (10.5-25.0)  99.8 (99.8-99.8)  22.9 (21.9-24.0)  <0.0001  0.578      
                        
HOSPITAL-BASED  
NON-DISEASE 
SPECIFIC  
                      
All   
  1.4  1  213  11.7 (7.7-16.4)  NA  NA  NA  NA  <0.0001    
    1.7  24  5759  26.0 (18.0-34.8)  98.0 (97.5-98.3)  7.0 (6.4-7.7)  <0.0001  0.034      
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    2.2  5  1547  13.4 (4.4-26.1)  97.1 (95.2-98.2)  5.8 (4.6-7.5)  <0.0001  0.975      
    4.5  1  100  2.0 (0.0-5.9)  NA  NA  NA  NA      
                        
                        
HOSPITAL-BASED 
DISEASE SPECIFIC  
                      
Bipolar mood disorder    1.7  1  130  53.1 (44.4-61.6)  NA  NA  NA  NA      
                        
CHD/HF    1.7  2  7003  20.5 (6.4-39.9)  94.7 (83.9-98.3)  4.4  <0.0001  NA      
                        
Groups  Subgroups  Cut-off, 
mmol/L  
N  
studies  
N 
participants  
% (95% CI)  I2 (95% CI)  H (95% CI)  P  
heterogeneity  
P Egger  
test  
P-diff 
criteria  
P-diff 
subgroups  
Diabetes mellitus    1.7  15  3484  35.5 (28.9-42.5)  94.2 (91.8-95.8)  4.1 (3.5-4.9)  <0.0001  0.198  0.080    
Diabetes mellitus    2.2  5  1154  26.0 (18.5-34.4)  89.0 (77.0-94.7)  3.0 (2.1-4.4)  <0.0001  0.602      
                        
Diabetic nephropathy    1.7  1  72  66.7 (55.3-77.1)  NA  NA  NA  NA      
                        
HIV    1.2  1  253  5.5 (3.0-8.7)  NA  NA  NA  NA  <0.0001    
HIV    1.7  34  70856  22.7 (20.2-25.4)  97.4 (96.9-97.8)  6.2 (5.7-6.7)  <0.0001  0.021      
HIV    2.2  8  8702  15.3 (8.2-24.1)  98.1 (97.3-98.6)  7.2 (6.1-8.5)  <0.0001  0.319      
                        
Hypertension    1.7  8  3781  22.2 (11.7-34.8)  98.4 (97.8-98.8)  8.0 (6.8-9.3)  <0.0001  0.271  0.0001    
Hypertension    4.5  1  100  2.0 (0.0-5.9)  NA  NA  NA  NA      
                        
Mental illness    1.7  1  276  14.5 (10.6-18.9)  NA  NA  NA  NA      
                        
Myocardial infarction    2.2  1  620  26.1 (22.7-29.7)  NA  NA  NA  NA      
                        
Obesity    1.7  3  219  17.9 (0.9-47.3)  94.8 (88.3-97.7)  4.4 (2.9-6.4)  <0.0001  0.370      
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Post-menopause    1.7  1  183  68.3 (61.4-74.9)  NA  NA  NA  NA      
                        
Pregnancy    1.7  2  725  65.7 (22.2-97.3)  97.5 (93.7-99.0)  6.3  <0.0001  NA      
                        
Psoriasis    1.7  1  150  34.0 (26.6-41.8)  NA  NA  NA  NA      
                        
Rheumatoid arthritis    1.7  1  92  34.8 (25.3-44.9)  NA  NA  NA  NA      
                        
Skin disease    1.7  1  300  3.3 (1.6-5.7)  NA  NA  NA  NA      
                        
Stroke    1.7  1  160  6.3 (2.9-10.6)  NA  NA  NA  NA      
                        
Systemic lupus 
erythematosus  
  1.7  1  221  35.7 (29.5-42.2)  NA  NA  NA  NA      
                        
POPULATION-BASED 
DISEASE SPECIFIC  
                      
Diabetes mellitus    1.7  5  2526  3.9 (1.2-7.7)  92.3 (85.1-96.1)  3.6 (2.6-5.0)  <0.0001  0.01      
Hypertension    2.2  1  710  18.0 (15.3-20.9)  NA  NA  NA  NA      
Obesity    1.7  1  154  13.6 (8.6-19.5)  NA  NA  NA  NA      
HIV: human immunodeficiency syndrome; MI: myocardial infarction; CHD: coronary heart disease; HF: heart failure  
  
  
  
Supplementary Figure 1. Prevalence of dyslipidaemia based on total cholesterol in patients with 
diabetes mellitus from hospital-based studies    
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Supplementary Figure 2. Prevalence of dyslipidaemia based on total cholesterol in patients with 
hypertension from hospital-based studies  
  
  
  
  
  
  
  
  
  
  
  
  
    
 
 37  
  
Supplementary Figure 3. Prevalence of dyslipidaemia based on total cholesterol in patients with 
human immunodeficiency virus from hospital-based studies   
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Supplementary Figure 4. Prevalence of dyslipidaemia based on total cholesterol in patients with 
human immunodeficiency virus on antiretroviral therapy from hospital-based studies  
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Supplementary Figure 5. Prevalence of dyslipidaemia based on high -density cholesterol in patients 
with diabetes mellitus from hospital-based studies  
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Supplementary Figure 6. Prevalence of dyslipidaemia based on high-density cholesterol in 
patients with human immunodeficiency virus on antiretroviral therapy from hospital-based 
studies  
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Supplementary Figure 7. Prevalence of dyslipidaemia based on high-density cholesterol in 
patients with human immunodeficiency virus from hospital-based studies 
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Supplementary Figure 8. Prevalence of dyslipidaemia based on high-density cholesterol in 
patients with hypertension from hospital-based studies   
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Supplementary Figure 9. Prevalence of dyslipidaemia based on low-density cholesterol in patients 
with diabetes mellitus from hospital-based studies  
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Supplementary Figure 10. Prevalence of dyslipidaemia based on low density cholesterol in 
patients with hypertension from hospital-based studies  
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Supplementary Figure 11. Prevalence of dyslipidaemia based on low density cholesterol in 
patients with human immunodeficiency virus on antiretroviral therapy from hospital-based 
studies  
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Supplementary Figure 12. Prevalence of dyslipidaemia based on low density cholesterol in 
patients with human immunodeficiency virus from hospital-based studies  
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Supplementary Figure 13. Prevalence of dyslipidaemia based on triglycerides in patients with 
diabetes mellitus from hospital-based studies  
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Supplementary Figure 14. Prevalence of dyslipidaemia based on triglycerides in patients with 
human immunodeficiency virus on antiretroviral therapy from hospital-based studies  
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Supplementary Figure 15. Prevalence of dyslipidaemia based on triglycerides in patients with 
human immunodeficiency virus from hospital-based studies  
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Supplementary Figure 16. Prevalence of dyslipidaemia based on triglycerides in patients with 
hypertension from hospital-based studies  
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 VIII- Addendum 
 
We performed meta-regression analyses to explore possible impact of study characteristics on the reported estimates (Tables 1-5). 
The study region, either central, eastern, northern, southern or western Africa, had an impact on the pooled prevalence of elevated 
triglycerides (cutoff of 1.7 mmol/L) in both univariate and multivariate analysis (Table 5). The country where studies were conducted 
did not influence pooled prevalence rates. The year of study publication had an impact on the pooled prevalence of low HDL cholesterol 
(cutoff of 1.0 mmol/L) in both univariate and multivariate analysis (Table 3). 
 
 
 
Table 1. Meta-regression analysis for elevated total cholesterol in the general population from community-based studies in 
Africa with a cutoff of 5.2 mmol/l 
Variables Univariable Multivariable* 
R², % Beta  95%CI-LB 95%CI-UB P value Beta  95%CI-LB 95%CI-UB P-value 
Year 0.0 0.002   -0.007    0.011 0.728    0.001 -0.008    0.009    0.891    
Region (Central) 15.0    0.092     
- Eastern  0.386 -0.001   0.774    0.324   -0.090 0.738    0.125 
- Northern  0.471   0.088   0.853    0.389   -0.026 0.804   0.066 
- Southern  0.475   0.084   0.867    0.475   0.065 0.885 0.023 
- Western  0.351   -0.025   0.726    0.349   -0.046    0.743  0.083 
Subnational (National) 6.1 -0.145  -0.297   0.008     0.062 -0.143   -0.341    0.054 0.156 
Number of studies = 37; * I² = 99.6%; R² = 6.8%; CI-UB: confidence interval of the upper bound; CI-LB: confidence interval of the lower bound 
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Table 2. Meta-regression analysis for elevated total cholesterol in the general population from community-based studies in 
Africa with a cutoff of 6.5 mmol/l 
Variables Univariable Multivariable* 
R², % Beta  95%CI-LB 95%CI-UB P value Beta  95%CI-LB 95%CI-UB P value 
Year 7.7 -0.005 -0.012    0.002    0.150   0.002   -0.007    0.010    0.740    
Region (Central) 25.2    0.021     
- Eastern  0.136   -0.137   0.409     0.137   -0.214    0.488    0.445    
- Northern  0.046   -0.234   0.325     0.062   -0.259    0.384    0.704    
- Southern  0.252   -0.114   0.619     0.295   -0.177    0.766    0.221    
- Western  -0.131   -0.430   0.168     -0.138   -0.471    0.196    0.418    
National (Subnational) 0.0 0.048 0.778 -0.287 0.660 0.030   -0.147    0.207    0.743    
Number of studies = 20; * I² = 99.2%; R² = 10.5%; CI-UB: confidence interval of the upper bound; CI-LB: confidence interval of the lower bound 
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Table 3. Meta-regression analysis for low HDL cholesterol in the general population from community-based studies in Africa 
with a cutoff of 1.0 mmol/l 
Variables Univariable Multivariable* 
R², % Beta  95%CI-LB 95%CI-UB P value Beta  95%CI-LB 95%CI-UB P value 
Year 22.8 0.027    0.010     0.044   0.001 0.027    0.012     0.043   <.001     
Region (Central) 6.0    0.361     
- Eastern  0.366   -0.125   0.857     0.401    -0.005     0.806     0.053    
- Northern  0.303   -0.157   0.763     0.252    -0.126     0.629      0.191    
- Southern  0.449   -0.011   0.909    0.434    0.059     0.810     0.023     
- Western  0.313   -0.132   0.758     0.246    -0.116     0.609      0.183    
Subnational (National) 7.8 0.118   -0.139   0.375      0.368 0.132    -0.095     0.358      0.254    
Number of studies = 27; * I² = 99.5%; R² = 38.6%; CI-UB: confidence interval of the upper bound; CI-LB: confidence interval of the lower bound 
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Table 4. Meta-regression analysis for elevated LDL cholesterol in the general population from community-based studies in 
Africa with a cutoff of 3.0 mmol/l 
Variables Univariable Multivariable* 
R², % Beta  95%CI-LB 95%CI-UB P value Beta  95%CI-LB 95%CI-UB P value 
Year 0.0 -0.007      0.738 -0.016   -0.083     0.052    0.651     
Region (Eastern) 0.0    0.876     
- Southern  0.044   -0.567   0.655     0.155    -0.659     0.969    0.709     
- Western  0.125   -0.412   0.662     0.197    -0.458     0.853    0.556     
Number of studies = 12; * I² = 99.7%; R² = 0.0%; CI-UB: confidence interval of the upper bound; CI-LB: confidence interval of the lower bound 
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Table 5. Meta-regression analysis for elevated triglycerides in the general population from community-based studies in Africa 
with a cutoff of 1.7 mmol/l 
Variables Univariable Multivariable* 
R², % Beta  95%CI-LB 95%CI-UB P value Beta  95%CI-LB 95%CI-UB P value 
Year 0.0 0.003   -0.004   0.010    0.440 0.006    -0.004   0.016    0.225    
Region (Central) 22.9    0.018     
- Eastern  0.246   >-0.001   0.492    0.291    0.010   0.572   0.043     
- Northern  0.298   0.060   0.537    0.350    0.073   0.627   0.013     
- Southern  0.231   -0.020   0.482    0.238    -0.058   0.534    0.115    
- Western  0.130   -0.110   -0.110  0.104    -0.159   0.367    0.440    
Subnational (National) 24.5 -0.166   -0.286   -0.045 0.007 -0.088   -0.282   0.106    0.376    
Number of studies = 37; * I² = 99.3%; R² = 38.1%; CI-UB: confidence interval of the upper bound; CI-LB: confidence interval of the lower bound 
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XI- Peer-reviewers’ comments and authors’ replies 
Below are the comments of the referees during the two rounds of peer-review by The Lancet Global 
Health. 
1- First review round  
REVIEWER # 1  
Reviewer’s Comment 1: The authors report only prevalence of lipid fraction abnormalities but not 
dyslipidemia according to International guidelines using any abnormality in lipid fractions such as the 
NCEP guidelines which include fasting total cholesterol =5.2 mmol/L, HDL cholesterol =1.03 mmol/l, 
triglyceride = 1.7 mmol/l or LDL cholesterol = 3.4 mmol/l. As reported by authors, there is potential for 
presenting a lower prevalence of dyslipidemia among Africans. For instance, the prevalence of 
dyslipidemia has recently been reported as 61% among controls and 78% among stroke cases in Ghana 
and Nigeria in the SIREN study.  
Dominant modifiable risk factors for stroke in Ghana and Nigeria (SIREN): a case-control study.  
Owolabi MO, Sarfo F, Akinyemi R, Gebregziabher M, Akpa O, Akpalu A, Wahab K, Obiako R, Owolabi 
L, Ovbiagele B; SIREN Team; as part of H3Africa Consortium. Lancet Glob Health. 2018 
Apr;6(4):e436e446.  
1. Could the authors specify if they came across any studies where these lipid fractions were used to 
compositely define dyslipidemia? Could the authors please synthesize and include additional analysis with 
such data?  
Authors’ response 1: Thank you for the comment. First, dyslipidemia was rarely defined using a 
combination of lipid variables. Furthermore, in the very few studies which did so, dyslipidemia was 
inconsistently defined across them. It was therefore impossible to conduct a meta-analysis of such data, 
given the heterogeneity in the definitions. Indeed, each individual form of dyslipidemia reported in our 
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meta-analysis (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, 
and triglycerides) was defined using different cut-offs. Consequently, there was huge variability in the 
composite definitions of dyslipidaemia based on various sets of lipid variables and various cut-offs. For 
this reason, we only pooled estimates based on individual cut-off for the different forms of dyslipidaemia 
of interest.  
We are mindful as already said in the manuscript and acknowledged by the reviewer, that the prevalence 
of dyslipidaemia from our review likely underestimate the true estimates of dyslipidaemia in Africa overall 
and by region. We are grateful to the reviewer for suggesting the recent report from SIREN study to 
substantiate the fact that prevalence from our review are likely underestimated. However, we do not 
believe that SIREN findings can be used to gauge the magnitude of this underestimation. The mean age 
of the control arm of SIREN was 58 years, that is not far from life expectancy in Africa which 61 years in 
men and 64 in women in 2017. Because the prevalence of dyslipidaemia increases with age, SIREN 
findings would likely apply to what will be considered as the elderly population (about 5% of the total 
population) in Africa, and not to a much broader (in term of age) population like our findings.  
  
Reviewer’s Comment 2: Can authors please present prevalence of dyslipidemia by age categories to help 
provide information on age distribution of dyslipidemia among Africans?  
Authors’ response 2: We thank the reviewer for raising this point. We were interested in presenting 
prevalence of dyslipidemias according to age categories in adults. Unfortunately, we could not find enough 
age-categorized data. Furthermore, there was significant overlap in the age categories across the rare 
studies which presented age-stratified data. Sub-group analysis according to age categories was therefore 
not possible.  
  
Reviewer’s Comment 3: Minor comments:  
 70  
  
Introduction:  
Please provide references for continental and regional estimates for diabetes and hypertension in 
paragraph 3 of introduction.  
Authors’ response 3: Thank you for the suggestion. A reference has been added.  
  
  
REVIEWER # 2  
Reviewer’s comment 1:    The authors systematically reviewed published studies on dyslipidemia and 
performed a meta-analysis. They found a summary prevalence of dyslipidemia of 23.6% in the general 
population, and got even higher prevalence among persons with some medical conditions.  
I feel that it is a good work and is acceptable in its present form for publication.  
Authors’ response 1:  We thank the Reviewer for the appreciation.  
  
REVIEWER # 3  
Reviewer’s comment 1: The studies included in the meta-analysis are mainly those of patients with 
underlying disease, namely diabetes, HIV infection or hypertension and not a healthy free-living 
population. It would have been better to restrict this meta-analysis to free-living persons rather than to 
those with underlying disease as it makes the results very difficult to interpret.  
Authors’ response 1: We read with great interest this comment and have the following observations: 1) 
using total cholesterol based dyslipidemia for illustration, we have included in our review 62 
communitybased non-disease specific studies with about 120,000 adult participants, and 25 hospital-based 
nondisease specific studies totalizing over 10,000 adult participants. By comparison, we have included 6 
community-based disease-specific studies (4592 participants), and 61 hospital-based disease-specific 
studies (49134 participants). This distribution is in sharp contradiction with the reviewer’s suggestion that 
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we have included in meta-analysis mainly studies of patients with underlying diseases instead of freeliving 
population. While there may be an interest in the reviewer’s suggestion to “restrict this metaanalysis to 
free-living persons rather than to those with underlying disease”, there is a merit in examining 
subpopulations. Indeed, information on the prevalence of various forms of dyslipidemia in subpopulations 
(i.e. disease-specific populations - HIV, diabetes mellitus and hypertension) allows a better understanding 
of the main drivers of the overall burden of the disease in the general population. One of the strengths of 
our study is to present useful data for researchers, clinicians and policymakers. Furthermore, with our 
current presentation allows a clear distinction between the overall and subpopulations estimates. Indeed, 
in the Results section, using sub-section titles, we clearly present pooled estimates from the general 
population and from populations with specific diseases, from studies conducted in the community  
(population-based studies) and those conducted in hospital (hospital-based studies). Therefore, we don’t 
think there should be difficulties in interpreting our results which are well stratified.  
  
Reviewer’s comment 2: All races are included, white, coloured, sub-Saharan black African and North 
African/Arab. As for point 1 this confounds and biases the results.  
Authors’ response 2: Thank you for this important comment. While we agree with the reviewer that it 
may be interesting to assess the prevalence by ethnic/racial groups, we do not see how the estimates of 
prevalence derived from a population will be confounded simply because of the multiethnic/multiracial 
nature of the population.   
Our systematic review and meta-analysis is constrained by the available data from relevant studies. We 
cannot present pooled estimates for various ethnic or racial populations across Africa because such data 
are not available. Furthermore, some ethnic groups such as whites do not represent a significant proportion 
of the African population to allow specific sub-group analysis. We however conducted subgroup-analysis 
 72  
  
for all the forms of dyslipidemia according to different regions in Africa using data from communitybased 
studies, shown in Supplementary Tables 1, 2, 3, and 4. Thus, specific pooled estimates for Northern 
African populations are therefore available.  
  
Reviewer’s comment 3: The cut-offs for lipids selected are rather arbitrary. In the text a cut-off of total 
cholesterol of 6.5 mmol/L is mentioned and is shown in Figure 2 but not discussed at all in the text. 
Authors’ response 3: We thank the Reviewer for this comment. The selection of cut-offs for lipid fraction 
selected is not arbitrary; it is explained in the Methods section. The studies included in this systematic 
review reported abnormal blood lipid level defined based on various cut-offs. Therefore, for consistency 
we grouped studies according to the cut-off used. Table 1 which summarizes the characteristics of included 
studies provides a clear distribution of studies according to cut-off. For instance regarding total 
cholesterol, 117 (70.1%) of studies used 5.2 mmol/L and 39 studies (23.3) used 6.5 mmol/L as the defining 
cut-off for dyslipidemia; with 3 other cut-offs being seldom used. It is not possible to present all the data 
in the main text of the manuscript due to space constraint and to avoid repetition of the results which are 
thoroughly presented in the tables, figures and the appendix. Therefore in the Results section, we presented 
data for the most frequently used cut-offs 5.2 mmol/L and  6.5 mmol/L. Furthermore, we also consider 
the cut-off which is recommended by guidelines. Regarding total cholesterol for instance, according to 
current guidelines, it is considered raised if above 5.2 mmol/L.  
Pertaining to the discussion, as mentioned above, we can only discussed the most salient findings.  
  
Reviewer’s comment 4: It would have been much better to have restricted this meta-analysis to 
SubSaharan Black Africans rather than all race groups as this is the population in which the prevalence of 
hyperlipidaemia, and the prevalence/incidence of atherosclerotic cardiovascular disease remain uncertain. 
In addition there is very little published data on the prevalence of familial hypercholesterolaemia (FH) in 
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black Africans. With the reported prevalence of at least 1: 500 if not 1:200 world-wide, with a population 
of over 1,2 billion people, one would expect over 1 million people in Africa to have FH but this has rarely 
been reported in Black Africans. How many of this meta-analysis cohort had an LDL-cholesterol > 5 
mmol/L which is suggestive of FH?  
Authors’ response 4: Thank you for this comment.  
While Black Africans may represent the majority of the population on the African continent, there are 
many other racial/ethnic groups. Any public health or clinical approach to effectively  and 
comprehensively address dyslipidemia on this continent should account for this fact. As we have also 
addressed these points in our responses to the comments 2 and 3, to avoid repetition we refer the reviewers 
to those responses. We have already indicated above that in addition to the overall pooled estimates across 
Africa, we have provided the results also by region (for community-based studies), which individualized 
northern Africa from other Africa region. However, the argument of dyslipidemia haven’t been better 
characterized in Northern than in sub-Saharan Africa, used by the reviewer to support his suggestion that 
our meta-analysis should be restricted to sub-Saharan Africa, is not supported by findings from the current 
review. In regional analysis of dyslipidemia from community based studies (supplementary Table 1 to 4); 
for total cholesterol-based dyslipidemia (TC>=5.2), Northern Africa had 9 studies (21381 participants) 
while Eastern Africa had 9 studies (41000 participants) and West Africa had 16 studies (15000 
participants). For high LDL the North had no studies.  
Regarding the cut-offs used, Table 1 provides a clear distribution of studies according to cut-off used to 
define dyslipidemia for each lipid fraction. As shown in this table, no studies used a cut-off of for 
LDLcholesterol 5 mmol/L.   
We appreciate the comment of the reviewer on familial hypercholesterolemia, but we believe that this 
inherited condition is better addressed in a dedicated review where other features of the conditions are 
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also investigated; and not in a general review like the current one where the focus is essentially on level 
of lipid variables.  
  
REVIEWER # 4  
Reviewer’s comment 1: 1. Abstract top heavy with results; par these down reporting key findings only. 
Authors’ response 1: Thank you for raising this point. Our study provides a significant amount of 
information on the prevalence of dyslipidemia in the general population and in key populations such as 
those with diabetes mellitus, hypertension and HIV, according to each of the four major forms of 
dyslipidemia including elevated total cholesterol, low HDL-cholesterol, elevated LDL-cholesterol and 
elevated triglycerides, with a precise diagnosis cut-off. We think that all the results presented in the 
abstract are relevant. We did our best to be concise.  
  
Reviewer’s comment 2: Was random effects an a priori choice, or from post-hoc analyses of your data? 
Note random effects (plural, see Forest plots).  
Authors’ response 2: Thank you for the comment. Random effect model was an a-priori choice, as 
described in the published protocol of this review (our reference #9 in the main manuscript).    
Reviewer’s comment 3: I would be tempted to include some of the publication bias in the main body of 
the paper. These tables are not the easiest to understand so detailed explanations are required rather than 
a passing comment.  
Authors’ response 3: We thank the reviewer for this comment. As indicated in the methods section (page  
7), we tested for publication bias using the Egger test. The various estimates of the test publication bias in 
Table 1 are for the various subgroups of studies. While we will be happy to follow the reviewer 
recommendation, we do not see how this can be done. The test of publication bias is relevant to the 
unpublished studies; it indicates how to put our results in context given that there may be unpublished 
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studies with potentially different prevalence estimates than the ones reported. We do not see how 
elaborating more on the test (s) for publication bias will help in better describing the results of the 
published studies presented in the tables (and in the text) other than it has been done now.  
  
Reviewer’s comment 4: Did you access the 'grey literature' (work ongoing but not yet published)?  
Authors’ response 4: We thank the reviewer for this suggestion. While we could explore the “grey 
literature”, we do not think that unpublished work would provide us with enough information to rigorously 
assess the quality of the studies. A rigorous assessment of the quality of the data (to ensure the accuracy 
of the estimates) was a key aspect of our systematic review, thus we focused published data since it is 
uncommon to have registered protocol for cross sectional studies.  
  
Reviewer’s comment 5: There are two columns headed 'Events'. Is the 2nd column the expected events 
from the meta-analysis? On further reading the 2nd column are proportions. Figure 5, x-axis scale should 
begin at 5 or 10%.  
Authors’ response 5: Thank you for these comments. Table 2 to 5 have been modified to address the 
issues raised.  
  
Reviewer’s comment 6: Meta-analysis is not with without it's critics or limitations (see e.g., Greenland 
S. Am j Epidemiol 1994; 140:783-787 and Bailor JC 3rd. New Eng J Med 1997; 337:559-561). Read and 
acknowledge.  
Authors’ response 6: Thank you for your comment. This has been highlighted in the discussion 
section/paragraph 8/lines 15 – 17.   
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Reviewer’s comment 6: Show the raw data (2x2 Table) on which the interrater agreement was based 
(Page 8, Kappa=0.81).  
Authors’ response 7: Of the 3315 studies remaining after removing the duplicates, 178 were classified 
as eligible and 3058 as non-eligible by the two reviewers. The two reviewers disagreed on the remaining 
studies with one reviewer classifying 32 of them as eligible and 47 as non-eligible while the other reviewer 
did the opposite. After reconciliation meeting three of these studies were classified as eligible and the 
remaining as non-eligible. In a 2x2 table, it will give the figure below, which has been added to the 
appendix section as ‘supplementary table 5’ and quoted in the main manuscript on page 8, paragraph 1.  
  
    Reviewer 1   Total reviewer 2  
    Eligible  Not eligible  
Reviewer 2  Eligible  178  32  225  
Not eligible  47  3058  3090  
Total reviewer 1  210  3105  3315  
  
Reviewer’s comment 8: Provide a PRISMA Statement.  
Authors’ response 8: The PRISMA checklist is provided as supplementary box 1, and referred to in the 
main manuscript on page 5, paragraph 1.  
  
2- Second review round  
REVIEWER # 3  
Reviewer’s Comment 1: The revised version of the manuscript is greatly improved and I am happy with 
the responses to most of my queries.    
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Authors’ response 1:  We thank the Reviewer for the appreciation.   
  
Reviewer’s Comment 2: However I do believe it is important for the authors to emphasize the limitations 
of the study, namely that it combined community bases and hospital based participants and, more 
importantly that the prevalence in the different ethnic/racial groups, particularly sub-Saharan black 
African (which represent the majority of the population on the African continent) was not possible. In 
addition a limitation of the study was that a breakdown of of the prevalence of dyslipidemia according to 
age categories was not possible.   
Authors’ response 2: We thank the reviewer for raising these suggestions regarding the limitations of 
our study. We have now elaborated on the absence of age-specific and ethnic specific estimates in the 
limitations section of the discussion on page 14 (please, see the relevant statement below). We have 
however also acknowledged that those are limitations of the primary studies and not necessarily those of 
the review we have conducted. Furthermore, with several hundred (and even thousand by some estimates) 
of ethnic groups found in Africa, it is unrealistic to believe (at least for the time being) that disease (or 
risk factor) estimates in Africa can be provided by ethnic group. Even the comprehensive Global Burden 
of Disease (GBD) group (with their huge resources) hasn’t provided disease burden estimate by ethnic 
groups in Africa. With reference to the reviewer’s assertion that we have combined community-based and 
hospital-based participants; we continue to believe that this is an overstatement. We have conducted 
stratified meta-analysis, always distinguishing throughout community-based from hospital-based studies, 
and in the interpretation, we do not believe that we have used community-based studies to make inference 
on hospital-based population and vice versa. We do not see our approach as a limitation, but rather as an 
attempt to provide a comprehensive picture of dyslipidaemia in Africa.   
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While estimates from community-based studies are for instance very relevant for the general population, 
for highly medicalized populations like people with HIV, diabetes, etc. estimates from hospital-based 
studies are highly relevant.   
“Finally, included studies did not provide age-specific and/or ethnic specific estimates, and therefore we 
were unable to derive pooled estimates of dyslipidaemia according to those major characteristics. Indeed, 
some variations in the prevalence of dyslipidaemia are expected across different age groups with highest 
prevalence in the elderly, and potentially across ethnic groups within African populations considering the 
racial/ethnic differences in dyslipidaemia patterns observed in American populations (Blacks, Asian 
Americans, Hispanics and non-Hispanic whites) for instance [37]. Realistically however, the huge ethnic 
diversity in Africa preclude any expectation that comprehensive and reliable ethnic-specific estimates of 
the disease burden/risk factors in Africa, could be generated through a study like the one we have 
conducted”  
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 IX-  PUBLISHED PROTOCOL  
The protocol which is presented below, was registered in the PROSPERO International Prospective 
Register of systematic reviews (number CRD42014015376) and published1.  
1. Noubiap JJ, Nansseu JR, Bigna JJ, Jingi AM, Kengne AP. Prevalence and incidence of 
dyslipidaemia among adults in Africa: a systematic review and meta-analysis protocol. BMJ Open  
2015; 5: e007404. 
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